פרופ' רונית אייזנברג שגיא

ביולוגיה תאית והתפתחותית סגל אקדמי בכיר
ניווט מהיר:
פרופ' רונית אייזנברג שגיא
טלפון פנימי: 03-6409500
טלפון נוסף: 03-6409320
פקס: 03-6407432
משרד: רפואה-סאקלר, 312

Positions

Professor, Cell & Development Biology, Sackler Faculty of Medicine, Tel Aviv University

Chair, Scholarship Committee, Graduate School of Medicine

 

Biography

Education

1974 B.Sc. in Chemistry, with distinction Tel Aviv University
1980 Ph.D. in Biochemistry Tel Aviv University
1980-1984 Postdoctoral fellow The Weizmann Institute of Science

 

תחומי מחקר

Mast cell function in health and disease

The primary interest of the Sagi-Eisenberg group is deciphering the mechanisms that dictate the consequences of mast cell activation. Indeed, mast cells are key effector cells whose activation results in the secretion of multiple inflammatory mediators, such as histamine and cytokines that cause allergic reactions, including skin allergy, food allergy and anaphylaxis. Mast cells derived mediators also play an important role in the amplification of chronic inflammatory diseases, including asthma, bowel diseases, autoimmune diseases, neurodegenerative diseases and cancer. However, on the other side of the coin, mast cells are part of the immune system, whose released mediators play protective roles in host defense mechanisms. Hence, deciphering the molecular mechanisms that drive mast cells from their protective immune functions, to their pathological function in allergy, inflammation and cancer is the focus of our studies. To that end, we combine up-to-date imaging with functional genomics driven screens to identify cellular proteins that control the release process during mast cells activation under experimental settings that recapitulate health and disease. Such proteins could serve as targets for the development of novel drugs that will eradicate the pathological function of mast cells in allergy, inflammation and cancer, while leaving their physiological functions intact.

We are currently recruiting students to participate in the following projects:

1)    Secretory granules size and mast cell cancer; Exploring their genetic connections.

2)    Migrating or secreting? The mechanism behind the decision-making.

3)    Mast cells and cancer- how to turn bad into good.

4)    Autophagy in mast cells –death or survival?

Publications & Grants

Recent Publications

Efergan A, Azouz NP, Klein O, Noguchi K, Rothenberg ME, Fukuda M, Sagi-Eisenberg R. Rab12 regulates retrograde transport of mast cell secretory granules by interacting with the rilp-dynein complex. J Immunol. 2016;196:1091-101.

 

Azouz NP, Fukuda M, Rothenberg ME, Sagi- Eisenberg R. Investigating mast cell secretory granules; from biosynthesis to exocytosis. J Vis Exp. 2015;95:52505.

 

Rudich N, Dekel O, Sagi-Eisenberg R. Downregulation of the A3 adenosine receptor in human mast cells upregulates mediators of angiogenesis and remodeling. Mol Immunol. 2015;65:25-33.

 

Azouz, N.P., Zur, N., Efergan, Ohbayashi, N., Fukuda, M., Amihai, D., Hammel, I., Rothenberg, ME and Sagi-Eisenberg, R. Rab5 is a novel regulator of mast cell secretory granules: impact on size, cargo and exocytosis. J Immunol. 192:4043-53 (2014)

 

Bar-Gill-Benado, A., Efergan, A., Seger, R., Fukuda, M., and Sagi-Eisenberg R. The extra-cellular signal regulated kinases ERK1 and ERK2 segregate displaying distinct spatiotemporal characteristics in activated mast cells. Biochim Biophys Acta. 1833, 2070-2082, (2013).

 

Bernstein-Molho R., Kollender, Y., Issakov, J., Bickels, J., Dadia S., Flusser, G., Meller, I., Sagi-Eisenberg. R. and Merimsky O. Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas. Cancer Chemother Pharmacol. 70, 855-860, (2012).

 

Azouz NP, Matsui, T., Fukuda, M. and Sagi-Eisenberg, R. Decoding the regulation of mast cell exocytosis by networks of Rab GTPases. J Immunol. 189, 2169-2180. (2012).

 

Gorzalczany Y, Gilad Y, Amihai D, Hammel I, Sagi-Eisenberg R, and Merimsky O. Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer. Cancer Lett. 310:207-215. (2011).

 

Baram D, Dekel O, Mekori YA, and Sagi-Eisenberg R. Activation of mast cells by trimeric G protein Gi3; coupling to the A3 adenosine receptor directly and upon T cell contact. J Immunol. 184:3677-3688. (2010).

 

 

Review

Rudich N, Ravid K, and Sagi-Eisenberg R. Mast cell adenosine receptors function: a focus on the A3 adenosine receptor and inflammation. Front Immunol. 3:134. (2012).

 

Siebenhaar F, Falcone FH, Tiligada E, Hammel I, Maurer M, Sagi-Eisenberg R, Levi-Schaffer F. The search for Mast Cell and Basophil models – Are we getting closer to pathophysiological relevance? Allergy 2015;70:1-5.

 

 

Grants

  • 2012-2015:  The Israel Science Foundation, Dissecting the molecular mechanisms underlying mast cell exocytosis; new insights provided by the small GTPase Rab5

אוניברסיטת תל-אביב, ת.ד. 39040, תל-אביב 6997801
UI/UX Basch_Interactive